Contact information:
Rebecca Passo
SHIFT Communications
(617) 779-1817
Rpasso@shiftcomm.com

PHARMAVIGILANT INVITES CROs TO BENEFIT WITH NEW PARTNERSHIP PROGRAM

Program Empowers CROs with a Best-in-Class Clinical Trial Technology Offering for their Pharmaceutical, Biotech and Medical Device Clients

WASHINGTON, D.C., June 14, 2010 – PharmaVigilant is pleased to announce its new CRO Partners Program, which invites all Clinical Research Organizations (CROs) to offer their Pharmaceutical, Biotech, and Medical Device clients with a full suite of clinical trial technology to better manage their clinical trial data with greater ease, speed and cost efficiency.

By partnering with PharmaVigilant, CROs can offer their sponsor customers' complete visibility into the technology solution, eliminating any blurred lines of accountability, one of the greatest outsourcing challenges the industry faces today. With PharmaVigilant's CRO Partnership Program, CROs will now have direct access to industry-leading clinical trial technology to better manage their clinical trial data with greater ease, speed and cost efficiency, while earning rewarding financial incentives.

According to James DeSanti, CEO and Founder of PharmaVigilant, "This program offers us the opportunity to broaden the reach of our technology by putting it directly into the capable hands of the clinical research organizations. This affords them the opportunity to be completely transparent in their sales process with their customers, alleviating any challenges associated with accountability."

PharmaVigilant's entire suite of technology includes Electronic Data Capture (EDC), data warehousing, study building (I-Builder), Electronic Trial Master File system (eTMF), Remote Source Document Verification (rSDV), study administration and an automated site payment system. PharmaVigilant focuses on Phase I-IV clinical trials, registries and other post-marketing studies. The technology has supported more than 200,000 patients in 18 countries across North America, Europe, Asia and Australia and continues to expand rapidly.

CROs globally are encouraged to participate in this rewarding partnership program. Additional incentives for participation include access to training and branded marketing materials. Companies interested in participating can visit www.pharmavigilant.com for more information or visit PharmaVigilant at Booth #2321 at the 2010 Drug Information Association Conference.

About PharmaVigilant:
Based in Westborough, Mass., PharmaVigilant is a technology company founded in 2005 to streamline the clinical trial process for biopharmaceutical companies. Its fully integrated suite of patient-based technology automates the collection and management of clinical trial data and most importantly puts that data in the sponsors' hands when and how they want it. Sponsors rely on PharmaVigilant to ease the regulatory and FDA submission and approval process and ultimately go to market more quickly with top quality drugs. For more information, visit www.pharmavigilant.com.